WILMINGTON, Del., March 31, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of Platform Specialty Products Corporation (NYSE:PAH)?
- Did you purchase your shares between February 17, 2015 and March 14, 2016, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. announces that a complaint has been filed in the United States District Court for the Southern District of Florida on behalf of all persons or entities that purchased the common stock of Platform Specialty Products Corporation (“Platform” or the “Company”) (NYSE:PAH) between February 17, 2015 and March 14, 2016, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you purchased shares of Platform during the Class Period, or purchased shares prior to the Class Period and still hold Platform, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/platform-specialty-products-corporation-pah.
The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.
According to the Complaint, on March 11, 2016, Platform disclosed in its 2015 annual report that the Company had “discovered certain payments made to third-party agents in connection with Arysta LifeScience Limited’s (“Arysta”) government tender business in West Africa which may be illegal or otherwise inappropriate” and had “engaged outside counsel and an outside accounting firm to conduct an internal investigation to review the legality of these and other payments . . . including Arysta’s compliance with the FCPA.”
Then, on March 14, 2016, shortly before the end of the trading day, the Wall Street Journal published a story addressing the disclosures by Platform in its 2015 annual report, entitled “Chemical Company Notifies U.S. of West Africa FCPA Probe.”
On this news, shares of Platform dropped over 7%, closing at $7.95 per share on March 15, 2016, on heavy trading volume.
If you wish to serve as lead plaintiff, you must move the Court no later than June 1, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com


Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 



